latest news releases from the newsroom
Global ePoint, Inc.
Global ePoint Announces Proposed Merger with Homeland Security Companies
SAN MARCOS, Calif., Jan. 21, 2003 (PRIMEZONE) -- Global ePoint, Inc. (Global) (Nasdaq:GEPT) today announced that it has signed a letter of intent to acquire 100 percent of the issued and outstanding stock or membership interest, as applicable, of Sequent Technologies, Inc., Best Logic, Inc., and McDigit, Inc (the "Companies").
Millicom International Cellular
Millicom International Cellular Nasdaq Listing and Detailed Results for the Quarter and Nine Months Ended September 30, 2002
NEW YORK, LONDON, and BERTRANGE, Luxembourg, Jan. 21, 2003 (PRIMEZONE) -- Millicom International Cellular S.A. ("Millicom") (Nasdaq:MICC), the global telecommunications investor, today announces that it has received written confirmation from The Nasdaq Stock Market, Inc. that Millicom would be delisted from the Nasdaq National Market unless its equity was raised to at least $10 million or it were able to maintain its minimum bid price per share at $3 for a period of ten consecutive trading days on or before February 17, 2003. Millicom also announces today a more detailed version of its results for the quarter and nine months ended September 30, 2002, previously announced on October 23, 2002.
Yanmar Exhibits Scania Engine for the First Time
SODERTALJE, Sweden, Jan. 21, 2003 (PRIMEZONE) -- The first results from cooperation between Scania Industrial and Marine Engines and Yanmar marine is shown for the first time at the Dusseldorf boat show in Germany. On display is a 12-litre marine engine for pleasure boats with 720 hp.
Novartis to Unite Its Generics Businesses Under One Single Global Brand: Sandoz
BASEL, Switzerland and KUNDL, Austria, Jan. 21, 2002 (PRIMEZONE) -- Novartis (NYSE:NVS) today unveiled plans to unite its 14 Generics company brands under a single global umbrella name, "Sandoz," to strengthen recognition and leverage share of voice in the highly competitive marketplace for generics (off-patent medicines). The initiative capitalises on the strong reputation of the Sandoz name, which still commands a high level of awareness and trust among physicians, pharmacists and patients.